Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NN-220 in Adults With Growth Hormone Deficiency
NCT00184743Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2003
- Primary completion
- Dec 2005
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatropin in growth hormone deficiency (GHD) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Percent change in truncal fat at 48 weeks. Started Dec 2003; status: completed.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT00184743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00184743.